Matches in SemOpenAlex for { <https://semopenalex.org/work/W2406322404> ?p ?o ?g. }
- W2406322404 endingPage "3183" @default.
- W2406322404 startingPage "3174" @default.
- W2406322404 abstract "The clonidine-like central antihypertensive agent rilmenidine, which has high affinity for I1-type imidazoline receptors (I1-IR) was recently found to have cytotoxic effects on cultured cancer cell lines. However, due to its pharmacological effects resulting also from α2-adrenoceptor activation, rilmenidine cannot be considered a suitable anticancer drug candidate. Here, we report the identification of novel rilmenidine-derived compounds with anticancer potential and devoid of α2-adrenoceptor effects by means of ligand- and structure-based drug design approaches. Starting from a large virtual library, eleven compounds were selected, synthesized and submitted to biological evaluation. The most active compound 5 exhibited a cytotoxic profile similar to that of rilmenidine, but without appreciable affinity to α2-adrenoceptors. In addition, compound 5 significantly enhanced the apoptotic response to doxorubicin, and may thus represent an important tool for the development of better adjuvant chemotherapeutic strategies for doxorubicin-insensitive cancers." @default.
- W2406322404 created "2016-06-24" @default.
- W2406322404 creator A5013666961 @default.
- W2406322404 creator A5013717837 @default.
- W2406322404 creator A5016372629 @default.
- W2406322404 creator A5019699822 @default.
- W2406322404 creator A5028871184 @default.
- W2406322404 creator A5031420130 @default.
- W2406322404 creator A5044944147 @default.
- W2406322404 creator A5045663508 @default.
- W2406322404 creator A5049064278 @default.
- W2406322404 creator A5050790487 @default.
- W2406322404 creator A5052758590 @default.
- W2406322404 creator A5056664099 @default.
- W2406322404 creator A5074076416 @default.
- W2406322404 creator A5078460231 @default.
- W2406322404 date "2016-07-01" @default.
- W2406322404 modified "2023-10-03" @default.
- W2406322404 title "A combined ligand- and structure-based approach for the identification of rilmenidine-derived compounds which synergize the antitumor effects of doxorubicin" @default.
- W2406322404 cites W125325141 @default.
- W2406322404 cites W1966172022 @default.
- W2406322404 cites W1984386298 @default.
- W2406322404 cites W1992345541 @default.
- W2406322404 cites W1992801434 @default.
- W2406322404 cites W1996955422 @default.
- W2406322404 cites W1996966884 @default.
- W2406322404 cites W2001816314 @default.
- W2406322404 cites W2005333494 @default.
- W2406322404 cites W2005666472 @default.
- W2406322404 cites W2015612871 @default.
- W2406322404 cites W2021256936 @default.
- W2406322404 cites W2025814748 @default.
- W2406322404 cites W2028768063 @default.
- W2406322404 cites W2029043996 @default.
- W2406322404 cites W2029542561 @default.
- W2406322404 cites W2032676191 @default.
- W2406322404 cites W2043474166 @default.
- W2406322404 cites W2052505313 @default.
- W2406322404 cites W2055664813 @default.
- W2406322404 cites W2062740079 @default.
- W2406322404 cites W2070111393 @default.
- W2406322404 cites W2074596190 @default.
- W2406322404 cites W2074631079 @default.
- W2406322404 cites W2078990877 @default.
- W2406322404 cites W2079053718 @default.
- W2406322404 cites W2081852949 @default.
- W2406322404 cites W2089168347 @default.
- W2406322404 cites W2096439168 @default.
- W2406322404 cites W2105715048 @default.
- W2406322404 cites W2114918609 @default.
- W2406322404 cites W2138213364 @default.
- W2406322404 cites W2145763605 @default.
- W2406322404 cites W2196076050 @default.
- W2406322404 cites W2204075485 @default.
- W2406322404 cites W2463036497 @default.
- W2406322404 cites W4293247451 @default.
- W2406322404 cites W939493718 @default.
- W2406322404 doi "https://doi.org/10.1016/j.bmc.2016.05.043" @default.
- W2406322404 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27265687" @default.
- W2406322404 hasPublicationYear "2016" @default.
- W2406322404 type Work @default.
- W2406322404 sameAs 2406322404 @default.
- W2406322404 citedByCount "14" @default.
- W2406322404 countsByYear W24063224042017 @default.
- W2406322404 countsByYear W24063224042018 @default.
- W2406322404 countsByYear W24063224042019 @default.
- W2406322404 countsByYear W24063224042020 @default.
- W2406322404 countsByYear W24063224042022 @default.
- W2406322404 countsByYear W24063224042023 @default.
- W2406322404 crossrefType "journal-article" @default.
- W2406322404 hasAuthorship W2406322404A5013666961 @default.
- W2406322404 hasAuthorship W2406322404A5013717837 @default.
- W2406322404 hasAuthorship W2406322404A5016372629 @default.
- W2406322404 hasAuthorship W2406322404A5019699822 @default.
- W2406322404 hasAuthorship W2406322404A5028871184 @default.
- W2406322404 hasAuthorship W2406322404A5031420130 @default.
- W2406322404 hasAuthorship W2406322404A5044944147 @default.
- W2406322404 hasAuthorship W2406322404A5045663508 @default.
- W2406322404 hasAuthorship W2406322404A5049064278 @default.
- W2406322404 hasAuthorship W2406322404A5050790487 @default.
- W2406322404 hasAuthorship W2406322404A5052758590 @default.
- W2406322404 hasAuthorship W2406322404A5056664099 @default.
- W2406322404 hasAuthorship W2406322404A5074076416 @default.
- W2406322404 hasAuthorship W2406322404A5078460231 @default.
- W2406322404 hasConcept C116569031 @default.
- W2406322404 hasConcept C123605464 @default.
- W2406322404 hasConcept C126322002 @default.
- W2406322404 hasConcept C134018914 @default.
- W2406322404 hasConcept C170493617 @default.
- W2406322404 hasConcept C185592680 @default.
- W2406322404 hasConcept C21951064 @default.
- W2406322404 hasConcept C2776694085 @default.
- W2406322404 hasConcept C2778399450 @default.
- W2406322404 hasConcept C2778938600 @default.
- W2406322404 hasConcept C2780307058 @default.
- W2406322404 hasConcept C2781303535 @default.
- W2406322404 hasConcept C55493867 @default.
- W2406322404 hasConcept C71240020 @default.